<SEC-DOCUMENT>0001279569-17-001085.txt : 20170518
<SEC-HEADER>0001279569-17-001085.hdr.sgml : 20170518
<ACCEPTANCE-DATETIME>20170517174543
ACCESSION NUMBER:		0001279569-17-001085
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170517
FILED AS OF DATE:		20170518
DATE AS OF CHANGE:		20170517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		17852893

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of May
2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS
REPORT </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">News Release Dated May 17, 2017 - ESSA Pharma Announces Data from Phase 1 Trial of EPI-506 to be Presented During 2017 ASCO Annual Meeting</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 17, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED MAY 17, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>&nbsp;<IMG SRC="essalogo.jpg" ALT="https:||mma.prnewswire.com|media|489324|ESSA_Pharma_Inc_ESSA_to_Present_at_Bloom_Burton___Co_Healthcare.jpg" STYLE="height: 111px; width: 338px"></B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><B>ESSA Pharma Announces Data from Phase 1 Trial of EPI-506 to be
Presented During 2017 ASCO Annual Meeting</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON and VANCOUVER, May 17, 2017 /CNW/ - ESSA Pharma Inc.
(TSX: EPI; NASDAQ: EPIX) (&quot;ESSA&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company focused on the
development of novel small molecule drugs for the treatment of prostate cancer, announced that early data from the Phase 1 portion
of the ongoing Phase 1/2 clinical trial of its product candidate, EPI-506, will be presented in a poster presentation at the upcoming
2017 American Society for Clinical Oncology (&quot;ASCO&quot;) Annual Meeting held June 2-6, 2017 in Chicago, Illinois. Information
contained in the abstract (http://iplanner.asco.org/am2017/#/session/11958) was as of the time of submission on January 31, 2017.
ESSA intends to announce updated results at the time of the poster presentation at the ASCO Annual Meeting.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Abstract 5032</B><BR>
<I>Efficacy, safety, tolerability and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal
domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or
abiraterone. </I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 8pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Presenter</B>:</FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Kim N. Chi, M.D., British Columbia Cancer Agency, Vancouver, BC</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Session Title</B>:</FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Genitourinary (Prostate Cancer)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Poster Board</B>:</FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">#106</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Date/Time</B>:</FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Monday, June 5, 2017 at 1:15pm &ndash; 4:45pm Central Time</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Location:</B></FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Hall A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">EPI-506 is currently in an open-label, single-arm Phase 1/2
dose-escalation study of end-stage patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed existing
treatments including abiraterone or enzalutamide, or both, and may have also received one prior line of chemotherapy.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">At the time of the abstract submission, minor PSA declines
in 3/18 patients had been observed at doses from 80 to 1280 mg. The respective human exposure at these dose levels correlate to
sub-therapeutic exposure derived from mouse xenograft studies. The data demonstrate that EPI-506 is well-tolerated with a favorable
safety profile, with pharmacokinetics indicating dose proportionality at doses up to 1280 mg. Since the submission of the abstract,
the company has completed one additional cohort of 2400 mg, and is currently enrolling patients in two additional cohorts dosed
at 3600 mg once-daily or 1800mg twice-daily (3600mg total daily dose).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">In a clinical study update in April 2017, ESSA reported that
pharmacological results confirmed that a dose of 2400 mg achieves drug exposures within the targeted therapeutic range. ESSA plans
to obtain additional data from a broader group of patients at higher dose levels to aid in the determination of an optimal Phase
2 dose.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About ESSA Pharma Inc. </B><BR>
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration
resistant prostate cancer (&quot;CRPC&quot;) in patients whose disease is progressing despite treatment with current therapies.
ESSA believes that its product candidate, EPI-506, can significantly expand the interval of time in which patients suffering from
CRPC can benefit from hormone-based therapies. Specifically, EPI-506 acts by disrupting the androgen receptor (&quot;AR&quot;)
signaling pathway, which is the primary pathway that drives prostate cancer growth. EPI-002, the primary metabolite of EPI-506,
prevents AR activation by binding selectively to the N-terminal domain (&quot;NTD&quot;) of the AR. A functional NTD is essential
for activation of the AR. Blocking the NTD prevents activation of the AR by all three known mechanisms of activation. In preclinical
studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms of CRPC. ESSA was founded
in 2009.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About Prostate Cancer</B><BR>
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide
(Globocan, 2012). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen
action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical
or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally
represents a transition to the lethal variant of the disease, mCRPC, and most patients ultimately succumb to the illness. The treatment
of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed
to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide,
or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease
progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies,
ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies
are no longer effective.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>This release contains certain information which, as presented,
constitutes &quot;forward-looking information&quot; within the meaning of the Private Securities Litigation Reform Act of 1995
and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often
addresses expected future business and financial performance, containing words such as &quot;anticipate&quot;, &quot;believe&quot;,
&quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;, statements that an action or event &quot;may&quot;,
&quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot; be taken or occur, or other similar expressions and
includes, but is not limited to, statements about the Company's Phase 1 clinical trial, including data and results thereof, and
the Company's planned announcement of such data and results; expectations regarding the initiation of the Phase 2 dose expansion
study, including statements about the dose levels and expected timing thereof; and the implementation of the Company's business
model and strategic plans.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking statements and information are subject
to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which
may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby.
Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are
inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and
contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) the Phase 1 portion of the Phase 1/2 clinical trial proceeding as expected;
(iii) obtaining positive results of clinical trials; (iv) obtaining necesarry &nbsp;regulatory approvals; and (v) general business,
market and economic conditions.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein and in ESSA's</I>&nbsp;<I>Annual Report on Form 20-F dated December
14, 2016 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile at the SEDAR website at www.sedar.com,
ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements
are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation
to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may
be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty
to forward-looking statements.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2017/17/c1846.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information:</B> Contact Information: Peter A. Virsik,
Chief Operating Officer, (832) 831-5958; David S. Wood, Chief Financial Officer, Tel: (778) 331-0962</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 17:12e 17-MAY-17</P>



<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0(L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     A < G@ +$534T$@4&AA<FUA($EN8RX@*$-.5R!'<F]U<"]%4U-!(%!H
M87)M82!);F,I' ):  =(3U535$].' )T 'U4:&ES(&EM86=E(&UU<W0@8F4@
M=7-E9"!W:71H:6X@=&AE(&-O;G1E>'0@;V8@=&AE(&YE=W,@<F5L96%S92!I
M="!A8V-O;7!A;FEE9"X@4F5Q=65S="!P97)M:7-S:6]N(&9R;VT@:7-S=65R
M(&9O<B!O=&AE<B!U<V5S+AP"90  ' )0  A(86YD+6]U=!P"7P "5%@< AD
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M&#*"D946-T)2559B<G62E*&QL]'3(T-4@Y/2%R0E)C,X8\$T-453HK*T_\0
M' $!  (# 0$!              4& P0' @$(_\0 .Q$  0," @8'!P0!! ,
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M5K]/1L+;+_E0N#XZ,/B=&8]*YOMM^"K8-TW53_EU=_;:G_'=_%/+J[^VU/\
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M-HX[>_G=6SM<TM#FG<'L(Y[K#YAEF,XI;GUV1WV@MD#&[\554-83X-:3NX^
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M=8^_(ZE9SH/F,6>Z2V3*&N;UU92@536_83L\R4>'GM/L(6WJ(WN:6;<%3>L
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,1$1$1$1$1$1$1?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
